2021
DOI: 10.1016/j.devcel.2021.02.011
|View full text |Cite
|
Sign up to set email alerts
|

Conversion of the death inhibitor ARC to a killer activates pancreatic β cell death in diabetes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

2
15
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
4
2

Relationship

1
5

Authors

Journals

citations
Cited by 8 publications
(17 citation statements)
references
References 85 publications
(110 reference statements)
2
15
0
Order By: Relevance
“…TIMP3 is a matrix metalloproteinase inhibiter and its deficiency is associated with renal interstitial inflammation and fibrosis [ 34 ]. Serpina1a is a serine protease inhibitor which has been shown to be downregulated in mice with diabetes [ 35 ]. Increased protease activity may lead to inflammation and tubular epithelial cell death in the UUO model.…”
Section: Discussionmentioning
confidence: 99%
“…TIMP3 is a matrix metalloproteinase inhibiter and its deficiency is associated with renal interstitial inflammation and fibrosis [ 34 ]. Serpina1a is a serine protease inhibitor which has been shown to be downregulated in mice with diabetes [ 35 ]. Increased protease activity may lead to inflammation and tubular epithelial cell death in the UUO model.…”
Section: Discussionmentioning
confidence: 99%
“…Apoptosis in type 2 diabetes is mediated both through the death receptor and mitochondrial pathways ( Liadis et al., 2007 ; Zhou et al., 2000 ). Although the precise signaling is incompletely understood, we recently described one relevant mechanism ( McKimpson et al., 2021 ).…”
Section: Before You Beginmentioning
confidence: 99%
“…The resulting information may be useful for mechanistic studies and assessment of the contribution of β-cell death to pathogenesis. For complete details on the use and execution of this protocol, please refer to McKimpson et al. (2021) .…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…Cardinal tissues of the body impacted by heightened insulin resistance (IR) and diminished insulin secretion in T2D include the pancreas, liver, skeletal muscle, and adipose tissue [13]. Alterations in the pancreas with T2D include the deposition of β-amyloid [14], reduced β-cell mass and increased β-cell apoptosis [15], as well as decreased size, irregularities of morphology and increased fat content [16]. A salient manifestation of T2D is the compromised insulin-mediated glucose uptake predominantly by skeletal muscle and to a lesser extent by adipose tissue resulting in hyperglycemia [17].…”
Section: Introductionmentioning
confidence: 99%